Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials
Xuan He,1 Ji Wang,2 Yuanmin Li3 1State Key Laboratory of Biotherapy, 2Department of Evidence-Based Medicine and Clinical Epidemiology, 3Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic...
Main Authors: | He X, Wang J, Li Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-08-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/efficacy-and-safety-of-docetaxel-for-advanced-non-small-cell-lung-canc-peer-reviewed-article-OTT |
Similar Items
-
Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
by: Liu J, et al.
Published: (2018-12-01) -
The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
by: Tadashi Sakaguchi, et al.
Published: (2020-06-01) -
Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials
by: Zheng Xiao, et al.
Published: (2018-01-01) -
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
by: Pavlakou Georgia, et al.
Published: (2010-11-01) -
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
by: Nan Bi, et al.
Published: (2020-04-01)